PMID- 8585003
OWN - NLM
STAT- MEDLINE
DCOM- 19960321
LR  - 20141120
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 74
IP  - 2
DP  - 1995 Aug
TI  - Chrono-pharmacological study of once daily curative dose of a low molecular 
      weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
PG  - 660-6
AB  - Low molecular weight heparin (LMWH) is currently prescribed for the treatment of 
      deep vein thrombosis at the dose of 100 IU antiXa/kg twice daily or at a dose of 
      175 IU antiXa/kg once daily with a similar efficacy. We decided to study the 
      chrono-pharmacology of curative dose of LMWH once daily administrated according 
      to the one previously described with unfractionated heparin (UFH). Ten healthy 
      volunteers participated in an open three-period crossover study according to 
      three 24 h cycles, separated by a wash-out interval lasting 7 days: one control 
      cycle without injection, two cycles with subcutaneous injection of 200 IU 
      antiXa/kg of Dalteparin (Fragmin) at 8 a.m. or at 8 p.m. Parameters of heparin 
      activity were analysed as maximal values and area under the curve. Activated 
      partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT) and 
      tissue factor pathway inhibitor (TFPI) were higher after 8 p.m. injection than 
      after 8 a.m. injection (p < 0.05) while no chrono-pharmacological variation of 
      anti factor Xa (AXa) activity was observed. Thus the biological anticoagulant 
      effect of 200 IU antiXa/kg of Dalteparin seems to be higher after an evening 
      injection than after a morning injection. A chrono-therapeutic approach with 
      LMWH, as prescribed once daily, deserves further investigation since our results 
      suggest that a preferential injection time may optimise the clinical efficacy of 
      these LMWH.
FAU - Mismetti, P
AU  - Mismetti P
AD  - Saint-Etienne Thrombosis Research Group, CHU Saint-Etienne, France.
FAU - Reynaud, J
AU  - Reynaud J
FAU - Tardy-Ponce, B
AU  - Tardy-Ponce B
FAU - Laporte-Simitsidis, S
AU  - Laporte-Simitsidis S
FAU - Scully, M
AU  - Scully M
FAU - Goodwyn, C
AU  - Goodwyn C
FAU - Queneau, P
AU  - Queneau P
FAU - Decousus, H
AU  - Decousus H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Lipoproteins)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - EC 3.4.21.68 (Tissue Plasminogen Activator)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adult
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Factors/analysis
MH  - Circadian Rhythm
MH  - Cross-Over Studies
MH  - Dalteparin/*administration & dosage/pharmacokinetics/pharmacology
MH  - Drug Administration Schedule
MH  - Factor Xa Inhibitors
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Lipoproteins/analysis
MH  - Male
MH  - Partial Thromboplastin Time
MH  - Prothrombin Time
MH  - Thrombin Time
MH  - Tissue Plasminogen Activator/analysis
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
PST - ppublish
SO  - Thromb Haemost. 1995 Aug;74(2):660-6.